Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
THAP domain-containing protein 1 is a human DNA-binding transcription factor featuring a THAP domain, a type of C2CH zinc finger that coordinates a zinc ion via conserved cysteine and histidine residues. This domain allows the protein to bind particular DNA sequences, notably a consensus bipartite TxxGGGx(A/T) motif. THAP1 regulates gene expression, which is important for cell cycle progression, apoptosis, and cell proliferation. It interacts with other nuclear proteins such as PAWR in nuclear bodies. It is the causative gene for DYT6 dystonia, a rare, inherited movement disorder characterized by involuntary muscle contractions and speech impairment. Mutations in THAP1 disrupt DNA binding, directly linking its function to the disease phenotype. As a member of the THAP protein family, it plays diverse roles across eukaryotic development, though direct pharmacological targeting has not been established. It is not typically considered a receptor, enzyme, or transporter, but is therapeutically relevant due to its disease association.
No drugs directly target THAP1; mechanism relates to DNA binding and transcription regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on THAP domain-containing protein 1 (THAP1).